HER-Vaxx has completed Ph2, PD1-Vaxx has just started Ph2 this year and CF33 and Azer-Cel is schedule to complete Ph1/b end of this year so yes they are many years away from even getting their IP to Ph3 completion which is why investors in biotech start-up stock tend to invest in them for a T/O by BP as the IP advance in development.
Usually, only BP will have the fund and resource to complete Ph3 clinical trial but CF33 seem to be very different so it could follow a different path to commercialisation like Azer-Cel so both might not need 5 years but a few years from Ph2.
HER-Vaxx has completed Ph2, PD1-Vaxx has just started Ph2 this...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.4¢ |
Change
0.002(2.44%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.2¢ | 8.5¢ | 8.1¢ | $662.1K | 7.955M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 75148 | 8.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 1246545 | 9 |
View Market Depth
| Last trade - 10.30am 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
8.4¢ |
Change
0.002 ( 2.19 %) |
||||
| Open | High | Low | Volume | ||
| 8.2¢ | 8.5¢ | 8.2¢ | 2481607 | ||
| Last updated 10.47am 30/04/2024 ? | |||||
| IMU (ASX) Chart |